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Abstract
Background: HIV-1 integrase (IN) is an emerging drug target, as IN strand transfer inhibitors
(INSTIs) are proving potent antiretroviral agents in clinical trials. One credible theory sees INSTIs
as docking at the cellular (acceptor) DNA-binding site after IN forms a transitional complex with
viral (donor) DNA. However, mapping of the DNA and INSTI binding sites within the IN catalytic
core domain (CCD) has been uncertain.
Methods: Structural superimpositions were conducted using the SWISS PDB and Cn3D free
software. Docking simulations of INSTIs were run by a widely validated genetic algorithm (GOLD).
Results: Structural superimpositions suggested that a two-metal model for HIV-1 IN CCD in
complex with small molecule, 1-(5-chloroindol-3-yl)-3-(tetrazoyl)-1,3-propandione-ene (5CITEP)
could be used as a surrogate for an IN/viral DNA complex, because it allowed replication of
contacts documented biochemically in viral DNA/IN complexes or displayed by a crystal structure
of the IN-related enzyme Tn5 transposase in complex with transposable DNA. Docking
simulations showed that the fitness of different compounds for the catalytic cavity of the IN/5CITEP
complex significantly (P < 0.01) correlated with their 50% inhibitory concentrations (IC50s) in
strand transfer assays in vitro. The amino acids involved in inhibitor binding matched those involved
in drug resistance. Both metal binding and occupation of the putative viral DNA binding site by
5CITEP appeared to be important for optimal drug/ligand interactions. The docking site of INSTIs
appeared to overlap with a putative acceptor DNA binding region adjacent to but distinct from the
putative donor DNA binding site, and homologous to the nucleic acid binding site of RNAse H. Of
note, some INSTIs such as 4,5-dihydroxypyrimidine carboxamides/N-Alkyl-5-hydroxypyrimidinone
carboxamides, a highly promising drug class including raltegravir/MK-0518 (now in clinical trials),
displayed interactions with IN reminiscent of those displayed by fungal molecules from Fusarium sp.,
shown in the 1990s to inhibit HIV-1 integration.
Conclusion: The 3D model presented here supports the idea that INSTIs dock at the putative
acceptor DNA-binding site in a IN/viral DNA complex. This mechanism of enzyme inhibition, likely
to be exploited by some natural products, might disclose future strategies for inhibition of nucleic
acid-manipulating enzymes.
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Background
Inhibitors of the human immunodeficiency virus type 1
(HIV-1) integrase (IN) enzyme, represent a major
advancement in AIDS research, showing potent antiretro-
viral effects in advanced clinical trials [1-4]. However,
despite the decade-long studies in this field (reviewed in:
[2]), several questions on the interactions of IN with its
inhibitors have remained unanswered [1,2]. These
include: the docking site, possible interactions with metal
ions and viral DNA, the amino acids involved in binding,
the role of drug resistance mutations, and the conforma-
tions assumed by the inhibitors in complex with the
enzyme. Elucidation of these issues is crucial, given the
strict requirement of IN for insertion of proviral DNA into
the cell genome, leading to retroviral latency and persist-
ence during therapy [5].
IN belongs to a family of polynucleotidyl transferases/
esterases, comprising transposases, RNAses H, and the
Argonaut RNAse associated with Dicer (involved in the
gene-silencing pathway) [1,6]. These proteins display sim-
ilar 3D folding of the catalytic domain and a conserved
catalytic triad of metal-coordinating carboxylates. IN
catalyses at least two reactions: 1) 3' processing, and 2)
strand transfer [reviewed in: [1]] (Fig. 1). Briefly, once the
viral RNA is retrotranscribed into DNA by reverse tran-
scriptase, IN-catalyzed 3'-processing removes a 3' terminal
portion (usually a dinucleotide) at both ends of HIV-1
DNA (also referred to as donor DNA) (Fig. 1). After 3'
processing, IN multimers remain bound to both ends of
HIV-1 DNA, and these multimolecular structures, namely
pre-integration complexes, translocate to the nucleus [7].
The second reaction catalyzed by IN, i.e. strand transfer,
inserts both 3' ends of HIV-1 DNA into a host-cell chro-
mosome (referred to as target DNA or acceptor DNA).
Strand transfer leaves a five-base, single-stranded gap at
each junction between the integrated proviral DNA and
the host acceptor DNA, and a (usually) two-base flap at
the 5'-ends of the proviral DNA (Fig. 1). The newly
formed DNA molecule thus requires repair, likely in coor-
dination with cellular DNA repair enzymes [1]. The lack
of 5' cleavage before strand transfer is a major difference
between HIV-1 IN and transposases such as Tn5, Tn7 and
Tn10, which release a blunt-end transposable element
from donor DNA [8,9]. 5' strand cleavage has been shown
for Tn5 and Tn10 transposons to occur via a two-step
process whereby the 3' OH generated from the initial
strand cleavage attacks the 5' strand to form a hairpin, fol-
lowed by cleavage of the hairpin by attack from an acti-
vated water molecule [8,9] (Fig. 1).
IN inhibitors can be divided into dual inhibitors of 3'
processing and stand transfer (simply referred to as 3'P
inhibitors), and selective strand transfer inhibitors (INS-
TIs). A credible theory sees 3'P inhibitors as docking at the
HIV-1 DNA-binding site, and INSTIs as occupying the
position of acceptor DNA [1,10]. This theory is supported
by biochemical evidence [10,11]. IN inhibitors currently
in clinical trials belong to the INSTI group. Chemically,
they display a β-hydroxy carbonyl (Fig. 2), thought to
bind the (possibly) two metal ions coordinating the three
catalytic residues D64, D116 and E152 [2,12]. A crystal
structure of these novel antiretrovirals in an IN/DNA com-
plex is still far from being available, and full understand-
ing of the binding mode of these inhibitors has been
hampered by lack of information on some important
points. These include: 1) a three-dimensional (3D) struc-
ture of the catalytic core domain (CCD) presenting both
metal ions displayed by structurally related enzymes
[8,12-14] (only the metal between D64 and D116 is
present in some structures [15,16]); 2) the mobility of a
flexible loop in the CCD (residues 140–152, partially or
totally absent in most crystal structures and displaying
varying configurations when present in its entirety) [17];
3) crystallographic data on the IN/DNA interaction; 4) a
crystal structure of full-length IN (the three domains, N-
terminal, C-terminal, and CCD have been solved sepa-
rately, and their 3D folding in a catalytic complex is only
hypothetical) [1]. One crystal structure of Goldgur et al.
showed 1-(5-chloroindol-3-yl)-3-(tetrazoyl)-1,3-propan-
dione-ene (5CITEP), i.e. compound (2) (see Fig. 2), lying
between the three catalytic residues [16]. Unfortunately,
this structure displayed only one of the two possible metal
ions within the catalytic cavity. Although some attributed
the position of 5CITEP to physical entrapment during
crystallization (crystal packing), recent biochemical data
confirmed some of the contacts observed by Goldgur et al.
[10], but showed that 5CITEP, though presenting some
structural features of INSTIs, resembles more a 3'P inhibi-
tor [10], in line with enzyme inhibition data in the pres-
ence of Mg++ (i.e. the metal thought to act as a cofactor in
vivo) [18].
Given the increasing importance of selective INSTIs for
AIDS medicine and their novel mechanism acting upon a
protein/DNA complex, some two-metal IN models were
created by molecular modeling in an attempt to describe
inhibitor binding in silico [12,14]. However, the only
docking study using a protein/DNA complex was con-
ducted by Barreca et al. [19] As a surrogate platform, these
authors employed a 3D structure of Tn5 transposase in
complex with two metal ions and donor DNA. Other
models are however necessary, since susceptibility of HIV-
1 IN to INSTIs may be affected by few amino acid changes,
as shown by drug-resistance mutation studies [12]. More-
over, the available structures present the Tn5 enzyme in
complex with the blunt-end reaction intermediate which
is not produced by HIV-1 IN [20]. On the other hand, the-
oretical structures of the HIV-1 IN in complex with donor
DNA (obtained by molecular modelling and in-silico auto-Retrovirology 2007, 4:21 http://www.retrovirology.com/content/4/1/21
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Sequence of events in HIV-1 integration (left) and Tn5 transposition (right) Figure 1
Sequence of events in HIV-1 integration (left) and Tn5 transposition (right). HIV-1: I) donor DNA; II) integrase-cat-
alyzed 3' processing; III) integrase-catalyzed strand transfer; IV) product of strand transfer; V) DNA repair by cellular enzymes. 
Tn5 transposon: 1) donor DNA; 2) 3'processing; 3–4) 5' processing, consisting of loop formation (3) and generation of blunt-
ended DNA (4); 5) strand transfer; 6) repaired strand transfer product. Portions of the donor DNA that become integrated 
are shown in red. Acceptor DNA is shown in white. Portions of acceptor DNA repaired following the strand transfer reaction 
are shown in grey.Retrovirology 2007, 4:21 http://www.retrovirology.com/content/4/1/21
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Compounds mentioned in the present study Figure 2
Compounds mentioned in the present study. Note that the structure of 8-hydroxy-1,6-naphthyridine carboxamide, L-
870,810 is presented both in trans and cis forms (the latter also referred to L-870,8125) as described in Refs [37] and [31], 
respectively. The structure of raltegravir/MK-0518 was retrieved from Ref. [54]. All other structures are available in the NCBI 
website [45].
O OH
HN
N
N
N HN
O
Cl
N
N
N
OH
H
N
O
S
O
O
F
(2) 5-CITEP
(17) equisetin
(7) L-870,812 trans
(10) elvitegravir /
JTK-303 / GS 9137
N
O OH
F
O
OH
(3) L-731,988
N
OH
O
O
O
OH
F
Cl
N
H O
OH
H
HO
O H
O
NH
OH
HH
H
O
(6) L-870,810
O
HO
O O
OH
O O OH
O OH
HO
OH
O N
NH
N
F
OO H
N H
N
O
N
OH
NO
F
O N
N H
N
O
N
OH
N
N O
O
F
(8) L-870,812 cis
(18) oteromycin
(21) L-chicoric acid
(4) S-1360
N
N N
N
H2N O
P
OH
O
HO
HO
(1) adenylic acid
H
N
O
F
N
N
OH
HO
N
(15) 4,5-dihydroxypyrimidine 
carboxamide
O
OH
HO
HO
OO H
OH
(22) quercetin
N
N
N
N
H
N
F
OO H
O O
(9) 
naphthyridine 
carboxamide
N
N
O
H
N
H
H
N Cl
HN
N
N Cl
N
H
N
O
(12) primaquine
(13) 
chloroquine
(14)
quinacr
ine
O
OH
H
N
HO O
HO
H
H
(11) KHD161
N N H
N
F
O
O
N
H
O O
N N
OH
(16) raltegravir / MK-0518
O
O OH
OH
O
O
HO
OH OH
OH
(20) chaetochromin B
O
O
O
H
H
H
H
O
O
O
H
O H
O
O O
H
O OH
(23) curcumin dimethyl ether
(19) integric acid
O OH
O
OH
(5) diketo acid BRetrovirology 2007, 4:21 http://www.retrovirology.com/content/4/1/21
Page 5 of 15
(page number not for citation purposes)
mated docking) [21,22] can only hazardously be used as
a platform to study inhibitor binding, in the absence of
further validation. In-silico  docking of INSTIs at these
models would be the final step of a number of computa-
tional simulations (e.g. reconstruction of full-length IN,
protein/DNA docking), thus harboring the risk of becom-
ing extremely artificial. In the absence of suitable 3D
models, reliable information on the interactions of IN
with DNA and specific inhibitors is derived from cross-
linking experiments [10]. These studies, however,
detected only few protein/DNA contacts and cannot fur-
nish a full 3D view of the complex.
Using a 3D platform exploiting crystallographic data on
IN CCD in complex with 5CITEP as a surrogate model for
in-silico docking simulations of INSTIs, the present study
provides a first view into an IN active site harbouring the
new antiretrovirals. The computational procedures
adopted here bypass artificial steps such as in-silico recon-
struction of full-length IN and IN/DNA complexes, and
are limited to one small-molecule inhibitor docking step,
using a widely validated genetic algorithm. The docking
solutions are in agreement with robust biochemical data
in the literature and may disclose new insights into inhi-
bition of an enzyme/substrate reaction intermediate.
Results and discussion
The Tn5 transposase/transposable DNA complex shows 
similarities with and differences from the HIV-1 IN/viral 
DNA interaction
To map the donor DNA-binding site within the catalytic
site of IN, previous work used the crystal structure of
inhibitor 5CITEP in complex with HIV-1 IN CCD
described by Goldgur et al. [22], or a structure of Tn5
transposase in complex with transposable DNA (corre-
sponding to proviral DNA) [19]. To compare these
approaches, a structural alignment of the two enzymes
was performed in the present study. The alignment
involved 75 amino acids including those facing the cata-
lytic cavity. The root mean square deviation (RMSD) was
0.17 Å between the α-carbons of the highly conserved cat-
alytic triads (IN: D64, D116 and E152; transposase: D97,
D188 and E326) (Fig. 3A). The 3D similarities between
HIV-1 IN and transposases have been extensively
described in the literature [for a review, see: [6]].
When the Tn5 DNA was transposed onto the HIV-1 IN
CCD structure, a close contact was observed between
K159 and the phosphate immediately 5' to the 3' terminal
nucleotide (Fig. 3B). One similar contact was described to
occur with the phosphate immediately 5' to the 3' process-
ing site of HIV-1 DNA [23], thus supporting the hypothe-
sis that the 3' terminal portions of transposable DNA and
HIV-1 3'processed (3'P)DNA occupy similar positions
within the active sites of the two enzymes. This hypothesis
is further supported by the overlap of the tetrazole ring of
5CITEP (a bioisoestere of the carboxylate anion) with the
phosphate contacting K159 (Fig. 3B). Although Tn5 DNA
and HIV-1 3'PDNA likely map to corresponding portions
of the active sites of the two enzymes, transposable DNA
per se cannot mimic HIV-1 DNA, because it is a blunt-end
reaction intermediate which is not generated in the reac-
tions catalyzed by HIV-1 IN (see Fig. 1). Moreover, the
experimental data clearly reveal a loop-like structure at the
5' terminus, a likely product of 5' processing (Fig. 3A–B).
Given these reasons, 5CITEP was, in the present study,
preferred over transposable DNA as an HIV-1 DNA
mimic. In line with this choice, a recent study [10] showed
that the contact of Q148 (in the flexible loop) with
5CITEP, displayed by the crystal structure of Goldgur et al.
[16], was reproducible in cross-linking experiments, and
that a similar contact occurred with the 5' terminal por-
tion of viral DNA, as well.
The nucleic acid binding site of Bacillus halodurans 
RNAse H likely corresponds to the cellular DNA binding 
site of HIV-1 IN
Tn5 transposase is not the only IN-related protein co-crys-
tallized in complex with a nucleic acid. Crystal structures
of RNAses H in complex with RNA/DNA hybrids have
been published, as well [24,25]. Of note, RNAses H are
susceptible to inhibition by INSTI-related compounds
[26]. To further explore possible IN/DNA interactions, a
structural alignment was performed between the IN crys-
tal structure of Goldberg et al. [16] and an averaged crystal
structure of Bacillus halodurans RNAse H in complex with
an RNA/DNA substrate published by Nowotny et al. [24].
This enzyme presents the advantage of being small and
limited to the basic "RNAse H" fold, also displayed by part
of the HIV-1 IN 3D architecture. The structural alignment
shown in Fig. 3C involved 45 amino acids with the mini-
mal RMSD (1.2 Å) at the level of those amino acids sur-
rounding D71 and D132 in the RNAse H, corresponding
to D64 and D116 of IN. The 3D similarities between HIV-
1 IN and RNAses H have extensively been discussed in the
literature [for a review, see: [27]].
When the RNA/DNA hybrid was transposed onto HIV-1
IN CCD, its projection mapped to a region within the cat-
alytic cavity, bordering with, but distinct from the putative
viral DNA-binding site, and delimited at either side by
lysine residues (K136 and K159). The positive charges fur-
nished by the metal(s) and the lysine residues are consist-
ent with a DNA-binding region. This hypothesis is
supported by structural alignments showing an overlap
between a phosphate bridge of the RNA/DNA hybrid and
a phosphate ion co-crystallized with HIV-1 IN by
Cherepanov et al. [28] (Fig. 3D). Given: 1) the existence of
a potential DNA-binding region adjacent to but distinct
from the donor DNA-binding site in the IN catalytic site,Retrovirology 2007, 4:21 http://www.retrovirology.com/content/4/1/21
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and 2) the correspondence of this region to a well docu-
mented nucleic acid-binding site in a structurally-related
enzyme (RNAse H), this region was hypothesized in the
present study to be the acceptor DNA-binding site.
Transposition of 5CITEP to a two-metal integrase model 
replicates contacts with flexible loop residues, Y143 and 
E148
To generate a surrogate platform for predicting docking of
INSTIs, a model of HIV-1 IN in complex with both puta-
Mapping of the nucleic acid-binding sites within the HIV-1 integrase (IN) catalytic site Figure 3
Mapping of the nucleic acid-binding sites within the HIV-1 integrase (IN) catalytic site. Panel A: Structural super-
imposition between the crystal structures of HIV-1 IN catalytic core domain (PDB accession code: 1QS4; in yellow) and Tn5 
transposase in complex with donor DNA (PDB: 1MM8; protein in green; DNA: in violet). The catalytic triads of IN and Tn5 
transposase are shown in red and black, respectively. Panel B: transposition of Tn5 donor DNA (carbon backbone in cyan) to 
a crystal structure (PDB:1QS4) of HIV-1 IN in complex with 1-(5-chloroindol-3-yl)-3-(tetrazoyl)-1,3-propandione-ene 
(5CITEP; carbon backbone in yellow). HIV-1 DNA-interacting residues Q148 and K159 are shown as sticks. Hydrogens have 
been removed for better clarity. The metal ion crystallized with IN is shown in magenta. Panel C: Structural superimposition 
between the crystal structures of HIV-1 IN catalytic core domain (in yellow), and Bacillus halodurans RNAse H in complex with 
an RNA/DNA hybrid (PDB: 1ZBL; protein: in cyan; nucleic acid: in smudge green). The catalytic triads of IN and RNAse H are 
shown in red and black, respectively. Panel D: Transposition of B. halodurans RNA/DNA hybrid (carbon backbone in green) to 
HIV-1 IN. Putative DNA-interacting residues, K136 and K159 (from right to left) are shown as sticks. A phosphate (in yellow) 
co crystallized with IN (PDB: 2B4J) had been added by superimposing the 2B4J structure to the IN structure (PDB: 1QS4) used 
as reference structure in this part of the present study.
A
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tive metal ions was first prepared based on homology
with Rous sarcoma virus (RSV) IN. For this purpose, a
structure of RSV IN CCD in complex with two metal ions
[13], was superimposed to the HIV-1 IN CCD crystal
structure of Maignan et al. Similarly to all HIV-1 IN struc-
tures in complex with metals, the structure of Maignan et
al. presents only one metal ion in the catalytic cavity, but,
differently from other published HIV-1 IN structures, dis-
plays a well ordered catalytic triad [15]. In one subunit of
this structure (chain C), the flexible loop is present in its
entirety and connects two CCD subunits in a dimer that
may have biological significance, as the distance between
the two active sites corresponds to 18 Å (see PDB: 1BL3),
approximately one half turn of a Watson-Crick DNA helix
(i.e., the distance at which the two antiparallel strands of
acceptor DNA are simultaneously nicked during strand
transfer [1,2]). The structural superimposition between
the HIV-1 IN CCD and the two-metal RSV IN CCD struc-
ture involved 104 amino acids with a RMSD of 0.24 Å
between the α-carbons of the highly conserved catalytic
triads (D64, D121 and E157 for RSV IN). The position of
the metal ion between D64 and D116 of HIV-1 IN and the
metal ion between D64 and D121 of RSV IN was approx-
imately coincident (data not shown). Then, the metal ion
between residues D64 and E157 of RSV IN (correspond-
ing to D64 and E152) was transposed onto HIV-1 IN
CCD, and the E152 side chain of HIV-1 IN was moved to
metal-coordinating position (matching that of the equiv-
alent residue in RSV IN).
To obtain a surrogate model for a two-metal IN CCD in
complex with viral DNA, the 3D coordinates of 5CITEP
were extracted from the structure of Goldgur et al. [16] and
transposed onto the two-metal model of HIV-1 IN CCD.
In the newly generated complex, it was possible to place
the aforementioned DNA-interacting residue Q148 at
hydrogen bonding distance from the inhibitor by rotating
the Cα-Cβ bond of the side chain by approx. 45° (Fig. 4).
Moreover, it was possible to show an additional close con-
tact of 5CITEP with another residue of the flexible loop,
i.e. Y143 (not present in the 1QS4 structure), known to
interact with HIV-1 DNA [28] (Fig. 4). Thus, the two-
metal/IN CCD in complex with 5CITEP allowed replica-
tion of contacts occurring between HIV-1 IN and viral
DNA.
In Silico docking fitness of HIV-1 integrase strand transfer 
inhibitors (INSTIs) for the catalytic cavity of integrase in 
complex with 5CITEP correlates with the in-vitro 
inhibitory potencies
The two-metal/IN-CCD/5CITEP complex was used as a
surrogate platform for docking simulations of IN inhibi-
tors, i.e. compounds (3–23) (see Fig. 2). Computational
simulations were conducted using the automated docking
program GOLD 3.1 and the GOLD fitness function to
rank the compounds on the basis of their ability to form
favorable interactions. Results showed that the GOLD fit-
ness scores of the best docking solutions correlated with
the IC50 for strand transfer in vitro (R = -0.73; P = 0.001;
see Fig. 5). In general, the technique allowed to distin-
guish between 3'P inhibitors, e.g. compounds (11–13,17–
22) and selective INSTIs, e.g. compounds (3–10,15,16).
The latter displayed high GOLD fitness scores (> 60).
Instead, the GOLD fitness scores were lower and unrelated
to the IC50 (P > 0.05) when conducted in the absence of
5CITEP, with or without the metal between D64 and E152
(data not shown).
The fitness scores obtained using the two-metal/IN-CCD/
5CITEP complex are higher that those obtained by Barreca
et al. (i.e., ~ 50) using the Tn5 transposase/DNA complex
[19]. This is not surprising, because INSTIs were devel-
oped using HIV-1 and not Tn5-based assays [2]. On the
other hand, the present study agrees with Barreca et al. that
the acidic INSTIs have similar fitness in both the proto-
nated and non-protonated form (data not shown).
These results allow the conclusion that occupation (by
5CITEP) of the putative donor DNA binding site is impor-
tant for obtaining optimal docking of INSTIs, in line with
a theory of Pommier et al. [1]. Moreover, the good agree-
ment between the experimental IC50 values and docking
solutions supports the idea that the two-metal/IN-CCD/
5CITEP complex could be used as a surrogate platform for
in-silico screening of potential INSTIs.
Docking of integrase strand transfer inhibitors (INSTIs) 
reveals unexpected metal-binding modes
The docking poses of five well known INSTIs, i.e. com-
pounds (3,4,6,7/8,10; see Fig. 2), were analyzed in further
detail (the 3D coordinates of the five compounds in com-
plex with IN CCD have been rendered available [see Addi-
tional files 1, 2, 3, 4, 56]). Diketo acid L-731,988, was one
of the first two INSTIs to furnish proof of concept for
antiretroviral effects in-vitro [30]. The best docking pose
for this compound showed the β-hydroxy keto pharma-
cophore chelating both metals (Fig. 6A). Diketo-acid ana-
log, S-1360 was the first INSTI to enter human clinical
trials [1,2]. Differently from L-731,988, the functional
groups of S-1360 showed, in the best docking pose, a pref-
erence for the putative metal between D64 and E152 (Fig.
6B). Both the pyrrole ring of L-731,988 and the furane
ring of S-1360 showed possible π-π interactions with the
indole moiety of 5CITEP. That these are false interactions
artificially generated by 5CITEP is unlikely, in light of the
structural similarity of the indole ring of 5CITEP and an
adenine (both 5' and 3'terminal nucleotides of HIV-1
3'PDNA are adenylates) (Fig. 2 and Fig. 6B). The 8-
hydroxy-1,6-naphthyridine carboxamides are an impor-
tant class of INSTIs [1,2]. Naphthyridine carboxamides, L-Retrovirology 2007, 4:21 http://www.retrovirology.com/content/4/1/21
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870,812 and L-870,810 were the first INSTIs to produce
proof of concept for in-vivo antiretroviral effects in mon-
keys and humans, respectively [2] A first set of docking
poses (henceforth referred to as set A) had intermediate
GOLD fitness scores (range: 60–65) and presented the
"classic" pharmacophore described by Merck researchers
(planar  β-hydroxy carbonyl plus coplanar lonely-pair
donor nitrogen [12]) chelating both metal ions (data not
shown). Other docking poses (referred to as set B) had
higher fitness scores (≅ 70; i.e. specifically related to
potent effects on strand transfer; according to the regres-
sion line of Fig. 5). Set B indicated preferential interac-
tions of the β-hydroxy carbonyl group with the metal
between D66 and E152. Interactions consistent with coor-
dination of the metal between D66 and D116 were
present as well, but were provided by oxygens in the sub-
stituents (an acyclic amide in L-870,812, and a cyclic sul-
phonamide in L-870,810). Set B1, including the best
ranked solution for L-870,812, displayed a β-hydroxy car-
bonyl that was not coplanar, due to rotation of the carbox-
amide group (in Fig. 6C, the acyclic amide substiturent is
in cis, as described in Ref. [31]; see structure 8 in Fig. 2).
Rotation of the carboxamide group has been observed in
other aromatic carboxamides in complex with enzymes
[32,33]. Solution set B2 included the best docking solu-
tion for L-870,810 (Fig. 6D). Docking poses B1 and B2
displayed the naphthyridine rings partially overlapping
on the same plane, but pose B2 slid aside from B1, thus
allowing optimal positioning of the cyclic sulphonamide
substituent of L-870,810 in the pocket containing the
metal between D64 and D116. The docking poses of the
naphthyridine carboxamides are in agreement with the
Interaction of integrase (IN) 3' processing inhibitor, 5CITEP with HIV-1 DNA-interacting residues Figure 4
Interaction of integrase (IN) 3' processing inhibitor, 5CITEP with HIV-1 DNA-interacting residues. 5CITEP is 
shown in CPK with an orange carbon backbone. Donor DNA-interacting residues are shown in color as sticks. The putative 
metal ions within the IN active site are shown as yellow spheres. Possible hydrogen bonds are shown as dashed lines. Hydro-
gens have been removed for better clarity.
K159
Q148
Y143Retrovirology 2007, 4:21 http://www.retrovirology.com/content/4/1/21
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novel pharmacophore described by Japan Tobaccos
researchers and displayed by elvitegravir (GS-9137), a 4-
quinolone 3-carboxylic acid currently in clinical trials
[3,34], which does not present the lonely pair donor
nitrogen coplanar to the β-hydroxy carbonyl. The best
docking pose for GS-9137 presented the β-hydroxy car-
boxylate chelating the metal between D64 and E152 and
a hydroxylic oxygen in the isobutyl substituent coordinat-
ing the other metal (Fig. 6E). In this docking solution, the
carboxylate is rotated by approx. 30° from the main qui-
nolone ring (Fig. 6E), in agreement with crystallographic
data showing rotation of aromatic carboxylates in com-
plex with metals [35].
The metal-binding mode is an unexpected finding of the
present study and is a major difference with the docking
results of Barreca et al. [19] and those of Merck researchers
[12]. Both research teams described metal chelation
through the "classic" pharmacophoric groups (i.e. a
coplanar β-hydroxy keto group, to which Merck research-
ers add a lonely pair donor atom). Differences between
the present study and that of Barreca et al. can of course be
attributable to differences between IN and transposase.
Differences with the Merck study are attributable to the
fact that these authors manually drove the INSTIs into an
uncomplexed IN active site [12]. It is finally possible that
both docking poses A and B coexist in vivo, given the alter-
native binding modes crystallographically documented
for other classes of antiretroviral drugs.
Docking of integrase strand transfer inhibitors (INSTIs) is 
concordant with the drug resistance mutation profiles
To further validate the docking results, the close contacts
of the INSTIs were related to well documented drug resist-
Correlation between the inhibitory potency of different compounds on HIV-1 integrase strand transfer and in-silico fitness for a  two-metal HIV-1 integrase core domain in complex with 5CITEP Figure 5
Correlation between the inhibitory potency of different compounds on HIV-1 integrase strand transfer and in-
silico fitness for a two-metal HIV-1 integrase core domain in complex with 5CITEP. x axis: the in-vitro inhibitory 
potency of the compounds is presented as a Log transform of the IC50 value retrieved from the NCBI database (Ref. [45]). y 
axis: the in-silico fitness is presented as a score automatically attributed by the GOLD program. The regression line best fitting 
the data points is shown as a solid line. Compounds are numbered as in Fig. 2.
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In-silicodocking of integrase strand transfer inhibitors (INSTIs) at the integrase (IN) active site Figure 6
In-silicodocking of integrase strand transfer inhibitors (INSTIs) at the integrase (IN) active site. The structure of 
INSTIs L-731,988 (Panel A), S-1360 (B), L-870,812 (C), L-870,810 (D), GS-9137 (E, F) is shown in CPK. The catalytic triad 
(D64, D116 and E152) is shown in the same color as the protein backbone. Metal ions are presented as yellow balls. Amino 
acids responsible for drug resistance are colored in magenta. Significant enzyme/ligand interactions are shown as dashed lines 
(hydrogen bonds in white, metal coordination in yellow, Van-der-Waals forces in red). An adenine (in orange), marking the ter-
minal portion of 3' processed viral DNA has been inserted by superimposition with the indole ring of 5CITEP. The adenine is 
shown for purely representative reasons, as the docking experiments were conducted in the presence of 5CITEP. A full 3D 
view of complexes in panels A-E can be obtained using the 3D coordinates provided as additional material [see Additional files 
1, 2, 3, 4, 56]. In panel F, superimposition between the IN/inhibitor complex and a crystal structure of RNAse H in complex 
with an RNA/DNA hybrid results in an overlap between the INSTI (GS-9137 is shown as an example) and the nucleic acid (evi-
denced in pale green).
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ance mutations selected by the same inhibitors. In its best
docking pose, diketo acid L-731,988 showed the carboxy-
late oriented towards T66, with possible hydrogen bond-
ing (Fig. 6A). In agreement with this docking pose, T66I is
a resistance mutation induced by L-731,988 which, alone,
decreases diketo acid susceptibility by 6-fold [30]. Hydro-
gen bonding was also possible with N155, mutation of
which was shown to confer cross-resistance to diketo acids
[12]. S-1360, which induces drug resistance mutations
similar to those selected by L-731,988 [36], also interacted
with T66 (Fig. 6B). The best docking pose for L-870,812
clearly showed the carbonyl oxygen of the rotated carbox-
amide group directly pointing to the amide group of
N155 (Fig. 6C), in perfect agreement with the drug resist-
ance mutation N155H (i.e. the only known L-870,812-
selected drug resistance mutation) [37]. The best docking
pose for L-870,810 showed the hydrophobic portion of
the sulphonamide ring in Van-der-Waals contact with the
F121 sidechain (Fig. 6D), in agreement with the primary
L-870,810 resistance mutation F121Y [12]. Van der Waals
contacts were also possible with N155 and E92, muta-
tions of which were shown to confer cross-resistance to
this inhibitor [12,38] (Fig. 6D). The best docking pose for
GS-9137 clearly presented the isobutyl substituent on the
quinolone oriented towards E92 (Fig. 6E). The hydroxyl
in the isobutyl substituent replaced one of the water mol-
ecules through which E92 coordinates the metal ion
between D64 and E152 (see PDB structure: 1BL3 in Ref.
[44]). Of note, a primary mutation induced by GS-9137 is
E92Q, which, alone, is capable of decreasing drug suscep-
tibility by 33-fold [38]. On the whole, the good agreement
between the drug resistance mutation profiles and the
docking poses represents a further validation of the results
obtained.
Docking of integrase strand transfer inhibitors (INSTIs) 
maps to the putative acceptor DNA binding site
Previous studies showing a dependence of the inhibitory
activity of INSTIs from the concentration of acceptor DNA
led to the hypothesis that INSTIs dock at the acceptor
DNA-binding site [1,11]. If 1) this hypothesis were cor-
rect, and 2) the binding sites of INSTIs and acceptor DNA
had correctly been predicted in the present study, then,
structural superimpositions should result in an overlap
between the docking solutions for INSTIs and the RNA/
DNA hybrid in complex with B. halodurans RNAse H.
Results showed that the docked INSTIs overlapped with
the RNA/DNA hybrid when the IN/inhibitor complexes
were superimposed to the B. halodurans RNAse H/sub-
strate crystal structure (Fig. 6F). This result further sup-
ports the hypothesis of Pommier et al. that INSTIs dock at
the acceptor DNA binding site of an IN/donor DNA com-
plex [1].
Integrase inhibitors in clinical trials are bioisosteric to 
fungal molecules is terms of metal binding
Interestingly, other drug classes that bind to a reaction
intermediate of an enzyme/substrate DNA complex (e.g.
topoisomerase inhibitors) are derived from natural prod-
ucts, thus raising the hypothesis that this type of inhibi-
tion is an enzyme inhibitory mode commonly adopted in
nature and resulting from evolution within dynamic sys-
tems [1,2]. Of note, equisetin (17) (Fig. 2), i.e. the first
molecule shown to inhibit strand transfer in pre-assem-
bled IN/viral DNA complexes, was extracted from myco-
toxin pools of Fusarium sp. [39], previously reported by
Savarino et al. to inhibit HIV-1 integration within live cells
[2,40,41]. Docking of equisetin and that of selective INS-
TIs were then compared. Interesting similarities were
found with the best docking solution for the novel INSTI,
compound (15), a member of the highly promising class,
4,5-dihydroxypyrimidine carboxamides/N-Alkyl-5-
hydroxypyrimidinone carboxamides, which includes
Merck's IN inhibitor raltegravir/MK-0518 (16) [42]. As
shown in Fig.7, there is a striking overlap of the metal-
coordinating groups, though not of the pending substitu-
ents. This result supports the previous idea that sesquiter-
penic fungal IN inhibitors (including equisetin), though
not yet acting as selective INSTIs, are different from other
3'P inhibitors. In line with this evidence, the GOLD fit-
ness score for the interaction between equisetin and the
two-metal/INCCD/5CITEP complex (i.e. 60) has previ-
ously been associated with enzyme inhibitory interactions
and was higher than those displayed by other 3'P inhibi-
tors such as L-chicoric acid (< 50). According to a model
of Lee and Robinson, docking of L-chicoric acid requires a
wide portion of the unengaged catalytic cavity [43]. The 3'
P inhibitors are a heterogeneous family of molecules [2].
It is possible to speculate that some 3' P inhibitors dock at
the donor DNA binding site, others occupy the entire cat-
alytic cavity, and molecules such as equisetin can adapt to
the catalytic cavity also when the donor DNA position is
occupied.
Conclusion
Molecular docking techniques may produce biologically
sound results also when applied to difficult drugs targets
such as an enzyme/substrate reaction intermediate. Occu-
pation by 5CITEP of the putative donor DNA-binding site
shows docking of INSTIs at a putative acceptor DNA-bind-
ing site. If future crystallographic data should confirm a
similar binding of INSTIs to a IN/donor DNA complex,
INSTIs might represent one of the few known drug types
acting on an enzyme reaction intermediate. Moreover,
novel INSTIs interact in silico with the metal cofactors sim-
ilarly to certain natural products such as Fusarium sp.
mycotoxins. This similarity suggests that it is possible to
identify natural products drug leads capable of dissecting
two different steps of an enzymatic process. The presenceRetrovirology 2007, 4:21 http://www.retrovirology.com/content/4/1/21
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of potential leads for drugs of this type in natural products
should encourage further natural product screening and
may disclose potential drug leads targeting other nucleic
acid manipulating enzymes such as the reverse tran-
scriptase-associated RNAse H.
Methods
Structural alignments
3D structures were retrieved from the Protein Data Bank
(PDB) [44], or from the U.S. National Center for Biotech-
nology Information (NCBI) website [45]. To obtain struc-
tural alignments, the α-carbons of the highly conserved
catalytic triads of HIV-1 IN and related enzymes were ini-
tially superimposed using the Swiss PDB Viewer (SPDBV)
program (Swiss Institute of Bioinformatics) [46], which
calculates the root-mean-square distance between the cor-
responding atoms using a least square algorithm. Using
the default matrix embedded in the program (with open
and extended gap penalties of 6 and 4, respectively) [46],
the calculation was extended to neighboring atoms until
the maximum number of aligned atoms with the lowest
RMSD was obtained. The program Pymol (v0.99; DeLano
Scientific LLC, S. Francisco, CA) (freely downloadable
from: [47]) was used to visualize the superimposed struc-
tures. Structural alignments were double-checked using
binary ASN1 files and the Cn3D program (version 4.1),
downloadable from the NCBI website [45].
Generation of a two-metal/integrase model
The crystal structure of HIV-1 IN CCD solved by Maignan
et al. [15] (PDB accession: 1BL3_C) was used as a basis for
modeling the IN CCD in complex with two metal ions.
Using SPDBV, this structure was superimposed to one
crystal structure of RSV IN CCD (PDB: 1VSH), where two
metal ions are present in the active site [13]. Using the 'tor-
sion' option embedded in the program, the E152 side
chain was moved to metal-coordinating position (match-
ing that of the equivalent residue in the RSV IN, E157).
The position of the metal between D64 and E152 was
deduced from the 3D coordinates of the corresponding
metal in the aligned RSV IN.
Molecular docking
The 3D structures of well characterized IN inhibitors
including INSTIs in clinical trials were initially generated
as pdb files using the CORINA web interface [48], on the
basis of the SMILES strings published in the NCBI website
[45]. The program VEGA ZZ (University of Milan, Italy;
freely available at: [49]) was adopted to assign the correct
bond types. The compounds were considered in their
keto-enol tautomeric form, since it has been clearly estab-
lished that these molecules mainly exist in this form in
solution (reviewed in: [2]). Moreover, both neutral and
ionic forms were generated for the carboxylic acid and tri-
azole groups of compounds. Using the default parameters
Superimposition of the best docking solutions for natural product integrase inhibitor equisetin from Fusarium sp. and a 4,5-dihy- droxypyrimidine carboxamide strand transfer inhibitor Figure 7
Superimposition of the best docking solutions for natural product integrase inhibitor equisetin from Fusarium 
sp. and a 4,5-dihydroxypyrimidine carboxamide strand transfer inhibitor. Compounds are shown in CPK. The car-
bon backbone of equisetin is displayed in yellow, that of the dihydroxypyrimidine carboxamide is in cyan. Metal ions are shown 
in black.Retrovirology 2007, 4:21 http://www.retrovirology.com/content/4/1/21
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in the VEGA program, force fields and charges were
assigned according to AMBER and Gasteiger algorithms,
respectively, and the molecules were energy-minimized
by 50 cycles of conjugate gradients (CG). Minimization
was stopped when the RMSD between two subsequent
solutions was lower than 0.1 Å. Energy minimized ligands
were then saved as mol files.
A surrogate platform for molecular docking of INSTIs was
generated by transposing the 3D coordinates of 5CITEP in
the structure of Goldgur et al. [16] onto the aforemen-
tioned two-metal model of HIV-1 IN CCD, after perform-
ing a structural alignment. Water molecules were
discarded from the pdb file, and missing side chains were
reconstructed using the option 'prepare file for docking pro-
grams' available at the WHAT-IF web interface [50].
Hydrogens were added using VEGA. The structure was
then subjected to energy minimization using the default
settings of the SPDBV program, i.e. 20 cycles of steepest
descent (SD), and minimization stopping when the Δ
energy was below 0.05 kJ/mol. The protein file was even-
tually converted to mol2 format using Mercury (v. 1.4.2;
Cambridge Crystallographic Data Centre (CCDC); freely
downloadable from: [51]). Automated docking studies
were then performed using the genetic algorithm GOLD
(Genetic Optimization for Ligand Docking) [52] (v. 3.1;
CCDC, Cambridge, UK), according to a protocol pub-
lished by Barreca et al. [19]. The algorithm had been pre-
viously validated and successfully tested on a data set of
over 300 complexes extracted from the PDB [53]. The pro-
gram was further validated in the author's hands by
obtaining docking poses for HIV-1 protease inhibitors
lopinavir and ritonavir nearly identical to the structures
co-crystallized in complex with the HIV-1 protease
(RMSD < 0.2 Å; data not shown). The binding site was ini-
tially defined as all residues of the target within 10 Å from
the metal atom coordinated by D64 and D116, and later
automated cavity detection was used. GOLD score was
chosen as fitness function and the standard default set-
tings were used in all calculations. For each of the 10 inde-
pendent genetic algorithm runs, a default maximum of
10,000 genetic operations was performed, using the
default operator weights and a population size of 100
chromosomes. Default cutoff values of 2.5 Å for hydrogen
bonds and 4 Å for Van der Waals interactions were
employed. The two metal ions were set to allow hexava-
lent coordination according to a Mg2+ type (i.e. the metal
thought to act as a co-factor in vivo). Carboxylate and car-
boxamide substituents on aromatic rings were allowed to
rotate. Early termination was allowed for results differing
by less than 1.5 Å in ligand all atom RMSD.
Post docking analysis was done using the program SILVER
(CCDC, UK), in order to evidence close contacts such as
hydrogen bonds and Van der Waals interactions.
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Additional material
Additional file 1
A two-metal model of HIV-1 integrase. This file contains the 3D coor-
dinates of the two-metal model of HIV-1 integrase described in the paper. 
Although the extension is .txt, it complies with a .pdb format. It can thus 
be opened with either programs such as MS Word or 3D molecular view-
ers such as the Swiss-PDB Viewer.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-4-21-S1.pdb]
Additional file 2
L-731,988 in complex with HIV-1 integrase catalytic core domain. 
This file contains the 3D coordinates of diketo acid, L-731,988, as docked 
at the model of HIV-1 integrase core domain in Additional file 1. Its for-
mat is the same as that of Additional file 1, and can be opened in combi-
nation with it so as to obtain a full view of this compound in complex with 
the two-metal model of HIV-1 integrase described in the paper.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-4-21-S2.txt]
Additional file 3
L-731,988 in complex with HIV-1 integrase catalytic core domain. 
This file contains the 3D coordinates of diketo acid analogue, S-1360, as 
docked at the model of HIV-1 integrase core domain in Additional file 1. 
Format and instructions for opening are the same as for Additional file 2
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-4-21-S3.txt]
Additional file 4
L-870,810 in complex with HIV-1 integrase catalytic core domain. 
This file contains the 3D coordinates of naphthyridine carboxamide, L-
870,810, as docked at the model of HIV-1 integrase core domain in Addi-
tional file 1 Format and instructions for opening are the same as for Addi-
tional file 2.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
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